Literature DB >> 20467319

Impact of dry eye disease and treatment on quality of life.

Neil J Friedman1.   

Abstract

PURPOSE OF REVIEW: Recent increased awareness of dry eye disease (DED) by both clinicians and patients has been accompanied by improved recognition that it is a chronic disorder often requiring long-term management. DED, frequently associated with symptoms of discomfort and visual disturbance, also impairs quality of life (QoL), including aspects of physical, social, and psychological functioning. This review summarizes the available research on the impact of DED and its treatment on measures of QoL. RECENT
FINDINGS: A relative dearth of data supporting the effectiveness of DED treatments as assessed by QoL measures exists. Both cyclosporine ophthalmic emulsion 0.05% and hydroxypropyl cellulose ophthalmic inserts have been associated with improvements in Ocular Surface Disease Index scores, a disease-specific measure of QoL, and with enhancement of patients' ratings regarding their ability to perform activities of daily living.
SUMMARY: Because there is a lack of concordance between symptoms and diagnostic measures of DED, QoL measures provide clinicians a valuable tool for assessing the burden of disease as well as response to treatment. Such measures should be employed in clinical practice and in future trials of treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467319     DOI: 10.1097/ICU.0b013e32833a8c15

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  76 in total

Review 1.  Antimicrobial compounds in tears.

Authors:  Alison M McDermott
Journal:  Exp Eye Res       Date:  2013-07-20       Impact factor: 3.467

2.  The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease.

Authors:  Munira Hussain; Roni M Shtein; Maxwell Pistilli; Maureen G Maguire; Marko Oydanich; Penny A Asbell
Journal:  Ocul Surf       Date:  2019-08-16       Impact factor: 5.033

Review 3.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

4.  Bilberry extract supplementation for preventing eye fatigue in video display terminal workers.

Authors:  Y Ozawa; M Kawashima; S Inoue; E Inagaki; A Suzuki; E Ooe; S Kobayashi; K Tsubota
Journal:  J Nutr Health Aging       Date:  2015-05       Impact factor: 4.075

5.  Efficacy of self-retained cryopreserved amniotic membrane for treatment of neuropathic corneal pain.

Authors:  Melina I Morkin; Pedram Hamrah
Journal:  Ocul Surf       Date:  2017-10-13       Impact factor: 5.033

6.  Dry Eye Following Phacoemulsification Surgery and its Relation to Associated Intraoperative Risk Factors.

Authors:  P K Sahu; G K Das; Aman Malik; Laura Biakthangi
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Oct-Dec

Review 7.  A review of quality of life measures in dry eye questionnaires.

Authors:  Joseph R Grubbs; Sue Tolleson-Rinehart; Kyle Huynh; Richard M Davis
Journal:  Cornea       Date:  2014-02       Impact factor: 2.651

8.  A thermo-responsive protein treatment for dry eyes.

Authors:  Wan Wang; Aarti Jashnani; Suhaas R Aluri; Joshua A Gustafson; Pang-Yu Hsueh; Frances Yarber; Robert L McKown; Gordon W Laurie; Sarah F Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2014-12-03       Impact factor: 9.776

Review 9.  Dry eye disease and microbial keratitis: is there a connection?

Authors:  Srihari Narayanan; Rachel L Redfern; William L Miller; Kelly K Nichols; Alison M McDermott
Journal:  Ocul Surf       Date:  2013-01-29       Impact factor: 5.033

Review 10.  Understanding Neuropathic Corneal Pain--Gaps and Current Therapeutic Approaches.

Authors:  Sunali Goyal; Pedram Hamrah
Journal:  Semin Ophthalmol       Date:  2016       Impact factor: 1.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.